

Highlights of This Issue 2009

FROM THE EDITOR-IN-CHIEF

2011 | **The Patient Impact Factor**

THE BEST OF MCT-10 YEARS

2012 | **Shining the Light on Aurora-A Kinase as a Drug Target in Pancreatic Cancer**
David J. Bearss

2013 | **First Report of Functional Chk1 siRNA Studies Applied to Drug Discovery**
Zehan Chen

2015 | **The Discovery and Development of SU14813, a Next-Generation Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Human Malignancies**
Dana Hu-Lowe, Nicoletta Brega, and Shem Patyna

2016 | **PI3K Inhibitors for Cancer Treatment: Five Years of Preclinical and Clinical Research after BEZ235**
Sauveur-Michel Maira

2017 | **Discovering and Developing PI3 Kinase Inhibitors for Cancer: Rapid Progress through Academic-Biotech-Pharma Interactions**
Florence I. Raynaud and Paul Workman

2019 | **The Discovery of Lapatinib (GW572016)**
David Rusnak and Tona M. Gilmer

2020 | **Methylation Profiling of Lung Cancer: A Decade of Progress**
Shinichi Toyooka and Adi F. Gazdar

2021 | **MicroRNAs in Cancer Pharmacology and Therapeutics: Exploiting a Natural Synergy between '-omic' and Hypothesis-Driven Research**
John N. Weinstein

2022 | **Development of the First Generation c-Met Kinase Inhibitors: Beginning of a Path to a New Treatment for Cancer**
Xueyan Wang, Gerald McMahon, and Kenneth E. Lipson

2024 | **Proof of Principle for Crizotinib in Anaplastic Lymphoma Kinase-Positive Malignancies Was Achieved in ALK-Positive Nonclinical Models**
James G. Christensen

2025 | **Lapatinib: Functional Genomics Study Leads to Insights into Mechanism of Action**
Tona M. Gilmer

2026 | **Bench to Bedside and Back Again: Personalizing Treatment for Patients with GIST**
Andrew K. Godwin

2028 | **The Importance of PK/PD Data-Key Biological Answers Needed to Evaluate the Success of Potential Cancer Therapeutics**
Rakesh Kumar and Benjamin Suttle

2029 | **Bortezomib: Understanding the Mechanism of Action**
Bilal Piperdi, Yi-He Ling, Leonard Liebes, Franco Muggia, and Roman Perez-Soler

2031 | **Starting with the ABCs: Akt in Breast Cancer**
Kip A. West and Phillip A. Dennis

2032 | **Cell Line Models Identify Different Sensitivity of Mutant Forms of c-KIT to Kinase Inhibitory Drugs and Predict the Response of Patients to Therapy**
Leonie K. Ashman

REVIEW

2034 | **Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma**
Teru Hideshima, Paul G. Richardson, and Kenneth C. Anderson

THERAPEUTIC DISCOVERY

- 2043 | **Identification of Small-Molecule Inhibitors of the Colorectal Cancer Oncogene Krüppel-like Factor 5 Expression by Ultrahigh-Throughput Screening**
Agnieszka B. Bialkowska, Melissa Crisp, Thomas Bannister, Yuanjun He, Sarwat Chowdhury, Stephan Schürer, Peter Chase, Timothy Spicer, Franck Madoux, Chenlu Tian, Peter Hodder, Daniel Zaharevitz, and Vincent W. Yang
- 2052 | **Discovery and Evaluation of Inhibitors of Human Ceramidase**
Jeremiah M. Draper, Zuping Xia, Ryan A. Smith, Yan Zhuang, Wenxue Wang, and Charles D. Smith
- 2062 | **Targeting the Intracellular MUC1 C-terminal Domain Inhibits Proliferation and Estrogen Receptor Transcriptional Activity in Lung Adenocarcinoma Cells**
Carolyn M. Klinge, Brandie N. Radde, Yoannis Imbert-Fernandez, Yun Teng, Margarita M. Ivanova, Sabra M. Abner, and Alexandra L. Martin
- 2072 | **A6 Peptide Activates CD44 Adhesive Activity, Induces FAK and MEK Phosphorylation, and Inhibits the Migration and Metastasis of CD44-Expressing Cells**
Randolph S. Piotrowicz, Bassam B. Damaj, Mohamed Hachicha, Francesca Incardona, Stephen B. Howell, and Malcolm Finlayson
- 2083 | **Digitoxin-Induced Cytotoxicity in Cancer Cells Is Mediated through Distinct Kinase and Interferon Signaling Networks**
Ioannis Prassas, George S. Karagiannis, Ihor Batruch, Apostolos Dimitromanolakis, Alessandro Datti, and Eleftherios P. Diamandis

PRECLINICAL DEVELOPMENT

- 2094 | **Combining Curcumin (Diferuloylmethane) and Heat Shock Protein Inhibition for Neurofibromatosis 2 Treatment: Analysis of Response and Resistance Pathways**
Laura S. Angelo, Ji Yuan Wu, Feng Meng, Michael Sun, Scott Kopetz, Ian E. McCutcheon, John M. Slopis, and Razelle Kurzrock

- 2104 | **Inactivation of Mirk/Dyrk1b Kinase Targets Quiescent Pancreatic Cancer Cells**
Daina Z. Ewton, Jing Hu, Maria Vilenchik, Xiaobing Deng, Kin-chun Luk, Ann Polonskaia, Ann F. Hoffman, Karen Zipf, John F. Boylan, and Eileen A. Friedman
- 2115 | **The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes MYCN-Amplified Neuroblastoma *In Vivo***
Amir Faisal, Lynsey Vaughan, Vassilios Bavetsias, Chongbo Sun, Butrus Atrash, Sian Avery, Yann Jamin, Simon P. Robinson, Paul Workman, Julian Blagg, Florence I. Raynaud, Suzanne A. Eccles, Louis Chesler, and Spiros Linardopoulos
- 2124 | **Activation of the Insulin-like Growth Factor-1 Receptor Induces Resistance to Epidermal Growth Factor Receptor Antagonism in Head and Neck Squamous Carcinoma Cells**
Mark J. Jameson, Andrew D. Beckler, Linnea E. Taniguchi, Amir Allak, Lisa B. VanWagner, Nora G. Lee, William C. Thomsen, Matthew A. Hubbard, and Christopher Y. Thomas
- 2135 | **Inhibition of Focal Adhesion Kinase by PF-562,271 Inhibits the Growth and Metastasis of Pancreatic Cancer Concomitant with Altering the Tumor Microenvironment**
Jayme B. Stokes, Sara J. Adair, Jill K. Slack-Davis, Dustin M. Walters, Robert W. Tilghman, E. Dan Hershey, Bryce Lowrey, Keena S. Thomas, Amy H. Bouton, Rosa F. Hwang, Edward B. Stelow, J. Thomas Parsons, and Todd W. Bauer
- 2146 | **3,5-Bis(2,4-Difluorobenzylidene)-4-piperidone, a Novel Compound That Affects Pancreatic Cancer Growth and Angiogenesis**
Dharmalingam Subramaniam, Nathan D. Nicholes, Animesh Dhar, Shahid Umar, Vibhudutta Awasthi, Danny R. Welch, Roy A. Jensen, and Shrikant Anant
- 2157 | **Targeting FGFR/PDGFR/VEGFR Impairs Tumor Growth, Angiogenesis, and Metastasis by Effects on Tumor Cells, Endothelial Cells, and Pericytes in Pancreatic Cancer**
Johannes Taeger, Christian Moser, Claus Hellerbrand, Maria E. Mycielska, Gabriel Glockzin, Hans J. Schlitt, Edward K. Geissler, Oliver Stoeltzing, and Sven A. Lang

MOLECULAR MEDICINE IN PRACTICE

- 2168 | **Tasisulam Sodium, an Antitumor Agent That Inhibits Mitotic Progression and Induces Vascular Normalization**
Timothy Meier, Mark Uhlik, Sudhakar Chintharlapalli, Michele Dowless, Robert Van Horn, Julie Stewart, Wayne Blosser, James Cook, Debra Young, Xiang Ye, Glenn Evans, Kelly Credille, Darryl Ballard, Lysiane Huber, Andrew Capen, Marcio Chedid, Robert Ilaria, Jr., Michele C. Smith, and Louis Stancato
- 2179 | **Antitumoral Effects of Calcitriol in Basal Cell Carcinomas Involve Inhibition of Hedgehog Signaling and Induction of Vitamin D Receptor Signaling and Differentiation**
Anja Uhmann, Hannah Niemann, Bérénice Lammering, Cornelia Henkel, Ina Heß, Frauke Nitzki, Anne Fritsch, Nicole Prüfer, Albert Rosenberger, Christian Dullin, Anke Schraepler, Julia Reifenberger, Stefan Schweyer, Torsten Pietsch, Frank Strutz, Walter Schulz-Schaeffer, and Heidi Hahn

- 2189 | **PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity**
Jing Yuan, Pramod P. Mehta, Min-Jean Yin, Shaoxian Sun, Aihua Zou, Jeffrey Chen, Kristina Rafidi, Zheng Feng, Jeffrey Nickel, Jon Engebretsen, Jill Hallin, Alessandra Blasina, Eric Zhang, Leslie Nguyen, Minghao Sun, Peter K. Vogt, Aileen McHarg, Hengmiao Cheng, James G. Christensen, Julie L.C. Kan, and Shubha Bagrodia
- 2200 | **A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models**
Genshi Zhao, Wei-ying Li, Daohong Chen, James R. Henry, Hong-Yu Li, Zhaogen Chen, Mohammad Zia-Ebrahimi, Laura Bloem, Yan Zhai, Karen Huss, Sheng-bin Peng, and Denis J. McCann

CORRECTION

- 2211 | **Correction: Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib**

ABOUT THE COVER

Met kinase homology model with its inhibitor, SU11271, docked in the ATP binding site. The cover image was selected from an article previously published in *Molecular Cancer Therapeutics*, which was chosen in celebration of the 10th anniversary of the journal. For details, see the commentary by Wang and colleagues on page 2022.



Molecular Cancer Therapeutics

10 (11)

Mol Cancer Ther 2011;10:2009-2211.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/10/11>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/10/11>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.